Currently, ongoing Phase 1 and 2 clinical trials are investigating the efficacy of RIG-I agonists in several tumor types, including gliomas, indicating the potential versatility of these therapeutic agents in inducing cell death and modulating cytokines (63, 64). Here, RIGI is linked to central nervous system cancer.